Phase Ib/II study of LGX818 and Cetuximab or LGX818, BYL719 and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Diseases and Conditions Researched

Colon; Rectum

What is the purpose of this trial?

Phase Ib: To estimate the MTD and/or RP2D of LGX818 in combination with cetuximab ± BYL719
Phase II: To compare the efficacy of the dual (LGX818, cetuximab) and triple (LGX818, BYL719, cetuximab) combinations.

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Novartis Pharmaceuticals
Last Updated:
Study HIC#: 1404013690